 |
Future of Drug DiscoveryAuthor: Murat Tunaboylu
The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments. Language: en Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
AI Statistical Programming for FDA Submissions - Louise Liu - #18
Episode 18
Wednesday, 20 May, 2026
In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research. The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months and eight million dollars is roughly what it takes to produce the data package for a single Phase 3 trial. Hill Research is doing that work with one person, in 90 minutes, with the help of generative AI. In this conversation, we get into how the technology works, what the FDA thinks about the use of AI in submissions, the accountability question pharma executives are asking, and what the next decade of clinical development could look like if the rest of the pipeline catches up.Be sure to like, rate and review the podcast if you enjoyed this episode! Links:Hill Research: https://www.hillresearch.ai/Louise’s LinkedIn: https://www.linkedin.com/in/louise-liu-phd-mba-hill-research/Visit our website: https://www.antiverse.io/Follow Antiverse: LinkedIn: https://www.linkedin.com/company/antiverse/ X: https://twitter.com/AntiverseHQ
